Trademark Search in Canada

LARIMAR

View On IC.GC.CA

REGISTERED

on 9 Nov 2022

Last Applicant/ Owned by

Larimar Therapeutics, Inc.

Three Bala Plaza East, Suite 506Bala Cynwyd PA 19004

Serial Number

2006442 filed on 22^nd Nov 2019

Registration Number

TMA1150213 registered on 9^th Nov 2022

Registration expiry Date

22^nd Nov 2029

Correspondent Address

SMART & BIGGAR LP

Scotia Plaza, 40 King Street West40th FloorToronto

ONTARIO

M5H3Y2

LARIMAR

Trademark usage description

pharmaceutical preparations for the treatment of mitochondrial disorders; pharmaceutical preparations for the treatment of diseases or dysfunction of Read More

Classification Information

Class [005]
Pharmaceutical preparations for the treatment of mitochondrial disorders; pharmaceutical preparations for the treatment of diseases or dysfunction of the mitochondria; preparations for the treatment of ataxia; pharmaceutical preparations for the treatment of Friedreich's Ataxia; pharmaceutical preparations for protein replacement therapy; pharmaceutical preparations and substances for treatment of genetic diseases, namely Friedreich's ataxia, Barth Syndrome, Parkinson's Disease, Wilson's Disease, Fibrosis, PLA2G6-associated neurodegeneration (PLAN), infantile neuroaxonal dystrophy (INAD), atypical neuroaxonal dystrophy (ANAD), adult onset dystonia parkinsonism (DP), autosomal recessive early-onset parkinsonism (AREP), Leigh Syndrome, lactic acidosis, myelin disorders, leukodystrophy, multiple sclerosis, Schilder's Disease, optic neuritis, acute disseminated encephalomyelitis (ADEM), acute hemorrhagic leukoencephalitis (AHL), paraneoplastic encephalomyelitis, rheumatoid arthritis, systemic lupus erythematosus, Behcet's disease, Sjorgen disease, Guillain-Barre Syndrome, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), paraproteinemic demyelinating neuropathy, progressive inflammatory neuropathy (PIN), anti-myelin associated glycoprotein (MAG) neuropathy, POEMS Syndrome, Charcot Marie Tooth Disease, copper deficiency associated disorder, human mitochondrial trifunctional protein deficiency, sudden infant death syndrome, Kearns-Sayre syndrome, Leber's Hereditary Optic Neuropathy, vanishing white matter disease (VWMD), X-Linked adrenoleukodystrophy (ALD), Vitamin B12 deficiency, central pontine myelinolysis, carbon monoxide poisoning, posterior reversible encephalopathy syndrome (PRES).

Classification kind code

Class [042]
Pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; research in the field of pharmaceuticals and drugs; conducting genomic analysis, preclinical studies and clinical trials for others in the field of pharmaceutical preparations for treatment of diseases.

Classification kind code

Mark Details

Serial Number

2006442

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 22 on 18^th May 2021	Search Recorded
Submitted for opposition 20 on 18^th May 2021	Examiner's First Report
Submitted for opposition 223 on 18^th May 2021	Total Provisional Refusal
Submitted for opposition 256 on 16^th Nov 2020	Notification of Possible Opposition Sent
Submitted for opposition 48 on 9^th Mar 2020	Agent Changed
Submitted for opposition 257 on 16^th Jan 2020	Designation Notification - Madrid Protocol
Submitted for opposition 31 on 15^th Jan 2020	Formalized
Submitted for opposition 1 on 15^th Jan 2020	Created
Submitted for opposition 228 on 22^nd Nov 2019	International Registration
Submitted for opposition 30 on 22^nd Nov 2019	Filed